Do You Want to Accelerate Quantitative Assays for Antibody Drug Conjugates?

Jun 23, 2017 | Biopharma, Blogs, Pharma | 0 comments

Are you tasked with the bioanalysis of antibody drug conjugates (ADCs)? If so, you know they represent a rapidly growing class of biotherapeutics, but their unique chemical structure makes quantitative analysis particularly challenging.

So, what is the best technique to create a novel quantitative analysis solution that accelerates method development and improves the performance of ADC pharmacokinetic assays?

Typically used Ligand binding assays (LBA) such as Enzyme-Linked Immunosorbent Assays (ELISA) have many advantages. However, LBAs can suffer from high variability, limited dynamic range, and problems with selectivity. An alternative comes with liquid chromatography-tandem mass spectrometry (LC-MS/MS), which has found widespread use in the quantitative analysis of small molecule drugs. While LC-MS/MS assays are exceedingly selective, with excellent dynamic range and reproducibility, they can lack sensitivity when applied to protein therapeutics.

In search of a solution, our experts developed a unique workflow with outstanding results. We combined a universal immunocapture enrichment strategy with sample preparation and a hybrid LBA microflow LC-MS/MS technique and applied it to the total antibody analysis of the ADC of Ado-trastuzumab emtansine in plasma.Read the full report in Chromatography Today >

Some of the highlights:

  • High capacity magnetic immunocapture beads coated with streptavidin and reagents from the SCIEX BioBA Sample Prep Kit accelerate method development for total antibody enrichment. The beads offer several advantages including ease of handling, scalability, improved sample recovery and parallel sample processing.
  • The use of microflow LC provides far superior sensitivity compared to traditional flow LC, enabling up to 5x lower LLOQ. Microflow LC is ideal for applications where you need quantification at low concentrations and/or where sample volumes are limited.
  • The SCIEX QTRAP® 6500+ with IonDrive™ Turbo V Source was used with a technique called multiple reaction monitoring (MRM). In MRM, the precursor ion of a specific analyte is selected in the first mass analyzer, fragmented in a collision cell and then one or more of the resulting product ions are monitored in the second mass analyzer. This provides an exceptionally selective and sensitive method for quantification.
  • Transitions and MS parameters were optimized using DiscoveryQuant™ software and kept constant for both experiments. Our MultiQuant™ 3.0.2 software performed data analysis.

Read the full article >

This hybrid LBA microflow LC-MS/MS workflow using high capacity streptavidin coated magnetic beads provides a customizable immunocapture strategy that enables the rapid development of high sensitivity pharmacokinetic assays of biotherapeutics during pre-clinical or phase HC studies.

The workflow applies to mAB based therapeutics and results in faster assay development with wide dynamic range, high selectivity, and high sensitivity, with a lower LLOQs than typically achieved by LC-MS/MS using a direct plasma or pellet digest.

Find out how our BioBA Solution can accelerate your biologics bioanalysis >

 

Understanding PFAS and its impact on U.S. drinking water

In recent years, per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing topic of interest due to their persistence in the environment and potential health risks. These synthetic compounds have been widely used in various industrial applications and consumer products since the 1940s. PFAS can be found in the air, soil, and water, and studies have shown that most people have detectable levels of PFAS in their bloodstream. One of the main exposure pathways for humans is through drinking water, particularly in communities located near industrial sites, military bases, or areas where firefighting foam has been used.

Selecting an LC-MS system for quantitation of pharmaceutical drug development

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial